--- title: "Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX" description: "Aberdeen Group plc increased its stake in Crinetics Pharmaceuticals, Inc. by 21.3% in Q3, owning 339,949 shares valued at $14.16 million. Other institutional investors also adjusted their holdings. An" type: "news" locale: "en" url: "https://longbridge.com/en/news/276426109.md" published_at: "2026-02-20T08:55:13.000Z" --- # Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX > Aberdeen Group plc increased its stake in Crinetics Pharmaceuticals, Inc. by 21.3% in Q3, owning 339,949 shares valued at $14.16 million. Other institutional investors also adjusted their holdings. Analysts have mixed ratings on CRNX, with Goldman Sachs upgrading it to "buy" and setting a target price of $67.00. The stock opened at $44.00, with a market cap of $4.50 billion. Insider Isabel Kalofonos sold 2,500 shares, reducing her position significantly. Crinetics focuses on developing therapeutics for rare endocrine diseases. Aberdeen Group plc boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 339,949 shares of the company's stock after buying an additional 59,602 shares during the period. Aberdeen Group plc owned approximately 0.36% of Crinetics Pharmaceuticals worth $14,159,000 as of its most recent filing with the Securities and Exchange Commission. A number of other institutional investors have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals by 11.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company's stock valued at $1,995,000 after purchasing an additional 6,148 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Crinetics Pharmaceuticals by 6.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company's stock worth $11,658,000 after purchasing an additional 22,305 shares during the period. Strs Ohio acquired a new position in Crinetics Pharmaceuticals in the 1st quarter valued at approximately $124,000. AlphaQuest LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the 2nd quarter valued at $799,000. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Crinetics Pharmaceuticals by 11.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,552 shares of the company's stock valued at $1,799,000 after acquiring an additional 6,674 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds. ## Analysts Set New Price Targets Several research analysts have weighed in on CRNX shares. The Goldman Sachs Group raised Crinetics Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $67.00 target price on the stock in a research report on Monday, January 12th. Wall Street Zen lowered shares of Crinetics Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, February 14th. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a "strong-buy" rating in a research report on Friday, February 13th. Citizens Jmp decreased their price objective on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a "market outperform" rating for the company in a report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $75.78. **View Our Latest Stock Report on Crinetics Pharmaceuticals** ## Crinetics Pharmaceuticals Price Performance CRNX opened at $44.00 on Friday. The company has a market capitalization of $4.50 billion, a P/E ratio of -9.71 and a beta of 0.19. The firm's fifty day moving average price is $49.42 and its two-hundred day moving average price is $42.47. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $24.10 and a fifty-two week high of $57.99. ## Insider Activity at Crinetics Pharmaceuticals In related news, insider Isabel Kalofonos sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the transaction, the insider owned 834 shares in the company, valued at $45,870. This trade represents a 74.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders. ## About Crinetics Pharmaceuticals (Free Report) Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence. The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea. ## Featured Articles - Five stocks we like better than Crinetics Pharmaceuticals - Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why - Unlocked: Elon Musk’s Next Big IPO - My Epstein Story - This $15 Stock Could Go Down as the #1 Stock of 2026 - What a Former CIA Agent Knows About the Coming Collapse **Want to see what other hedge funds are holding CRNX?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now? Before you consider Crinetics Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list. While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md) - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [CRNX.US - Crinetics Pharmaceuticals](https://longbridge.com/en/quote/CRNX.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Eupraxia Pharmaceuticals 宣佈其普通股和預先資助認股權證的 5500 萬美元公開發行定價 \| EPRX 股票新聞 | Eupraxia Pharmaceuticals Inc. 宣佈以每股 7.00 美元的價格公開發行 6,428,574 股普通股，以及以 6.99999 美元的價格發行預先融資的認股權證，預計總收益約為 5500 萬美元。該發行預計於 2 | [Link](https://longbridge.com/en/news/276310117.md) | | Madrigal 製藥因 Rezdiffra 的銷售，第四季度收入大幅增長 | Madrigal 製藥報告第四季度收入為 3.211 億美元，較去年大幅增長，儘管出現了淨虧損。該公司預計，由於疾病意識的提高，Rezdiffra 的銷售將實現強勁增長，並計劃與 FDA 就第二階段試驗設計進行諮詢。MASH 管道已通過新項 | [Link](https://longbridge.com/en/news/276330392.md) | | 津巴布韋推出新型 HIV 預防藥物 lenacapavir | 津巴布韋推出了長效 HIV 預防藥物 lenacapavir，目標是覆蓋超過 46,000 名高風險個體，分佈在 24 個地點。該項目由美國和全球基金資助，分階段進行，衞生部長道格拉斯·蒙貝肖拉強調了其在抗擊 HIV 中的重要性。lenac | [Link](https://longbridge.com/en/news/276333424.md) | | 解析 Ardelyx：7 位分析師分享他們的看法 | 在最新的季度中，7 位分析師對 Ardelyx（NASDAQ:ARDX）給出了混合評級，平均 12 個月目標價為 16.86 美元，比之前的目標上漲了 24.24%。主要分析師提高了他們的評級，其中 HC Wainwright、BTIG 和 | [Link](https://longbridge.com/en/news/276450068.md) | | Enanta 製藥：RSV 單克隆抗體的挑戰轉變為 Zelicapavir 治療機會的助力 | Enanta 製藥獲得了 H.C. Wainwright 分析師 Brandon Folkes 的買入評級，目標價為 20.00 美元。Folkes 認為，近期關於 RSV 的新聞對 Enanta 的主要資產 zelicapavir 產生了 | [Link](https://longbridge.com/en/news/276474081.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.